hyperlipidemia vs hypercholesteremia

Some examples from the web:

• The risk/ benefit should be considered in patients with established hyperlipidemia before initiating an immunosuppressive regimen including Rapamune.
• Similarly the risk/ benefit of continued Rapamune therapy should be re-evaluated in patients with severe refractory hyperlipidemia.
• This condition includes a number of diseases such as familial combined hyperlipidemia, other poorly characterised polygenic syndromes, and dysbetalipoproteinemia.
• In patients with combined hyperlipidemia and type 2 diabetes mellitus (n=24 randomized), observed dose-dependent percent changes from baseline were not different from those observed in nondiabetic patients.
• The study included men and women 21 to 70 years with combined hyperlipidemia defined as LDL cholesterol greater than 130 mg/ dl, and triglycerides between 300 and 700 mg/ dl at Weeks -4 and -2.
• Patients administered Rapamune should be monitored for hyperlipidemia using laboratory tests and if hyperlipidemia is detected, subsequent interventions such as diet, exercise, and lipid-lowering agents should be initiated.
• There are no signs of hyperlipidemia or pancreatitis.

Some examples from the web:

• Infusion-related pain primarily presenting as back pain, nausea, photosensitivity reaction, asthenia, hypercholesteraemia.
• I'm the one who diagnosed the familial hypercholesterolemia.
• Hypercholesterolemia still is an indication, but mainly in combination with such dyslipidaemia.
• The dosage of atorvastatin in patients with homozygous familial hypercholesterolemia is 10 to 80 mg daily.
• The dosage of atorvastatin in patients with homozygous familial hypercholesterolemia is 10 to 80 mg daily.
• Hypercholesterolemia Treatment of primary hypercholesterolemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate.
• Hypercholesterolemia Treatment of primary hypercholesterolemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate.
• hypercholesterolemia, weight gain, hyperglycemia, hunger
• Experience in pediatrics is limited to a small number of patients (age 4 - 17 years) with severe dyslipidemias, such as homozygous familial hypercholesterolemia.
• Primary hypercholesterolemia (Fredrickson's type's IIa and IIb) has been approved in all Member States, Iceland and Norway.
• Additionally, study 145 have some methodological deficiencies, e. g., the lack of a controlled group treated with nicotinic acid and the small number of patients included with isolated hypercholesterolemia.
• In this study 12 patients with homozygous familial hypercholesterolemia were randomized to simvastatin 40 mg administered as a single dose or 80 mg/ day (in 3 doses), following a 4-week diet/ placebo run-in phase.
• 4,444 patients with angina pectoris or previous myocardial infarction and hypercholesterolemia on a lipid-lowering diet were randomised to double-blind treatment with simvastatin or placebo and followed up for a median of 5.4 years.
• In patients with a known risk factor for cardiovascular disease, monitoring of the blood lipid levels is recommended, since hypercholesterolemia has been observed in a few cases in patients treated with glucosamine.
• - If you have a known risk factor for cardiovascular disease, since hypercholesterolemia has been
• Metabolic and nutritional disorders: avitaminosis, dehydration, oedema, increased appetite, lactic acidosis, obesity, anorexia, diabetes mellitus, hyperglycaemia, hypocholesteremia;
• Primary Hypercholesterolaemia and Combined Hyperlipidaemia In studies comparing the efficacy and safety of simvastatin 10, 20, 40 and 80 mg daily in patients with hypercholesterolemia, the mean reductions of LDL-C were 30, 38, 41 and 47%, respectively.
• Primary prevention Reduction of cardiovascular mortality and morbidity in patients with moderate or severe hypercholesterolemia and at high risk of a first cardiovascular event, as an adjunct to diet (see section 5.1).
• Primary prevention Reduction of cardiovascular mortality and morbidity in patients with moderate or severe hypercholesterolemia and at high risk of a first cardiovascular event, as an adjunct to diet (see section 5.1).
• Avitaminosis, dehydration, oedema, increased appetite, lactic acidosis, obesity, anorexia, diabetes, mellitus, hyperglycaemia, hypocholesteremia